Author: Jenny Cook

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

C3PO

Inclusion/Exclusion:

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

≥1 COVID-like sx for ≤7days
Confirmed COVID +
≥18yo
≥1 risk factor (age≥50y; HTN; diabetes; CAD; chronic lung or kidney disease; immunosuppressed; sickle cell, obesity(BMI>30)
Likely to be d/c’d home
No blood products, last 120d

C3PO

Inclusion/Exclusion:

C3PO

C3PO

C3PO

C3PO

C3PO

If pt COVID Positive

If pt COVID Positive

If pt COVID Positive

If pt COVID Positive

If pt COVID Positive

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

C3PO

C3PO

C3PO

C3PO

If pt COVID Positive

If pt COVID Positive

If pt COVID Positive

If pt COVID Positive

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

Page #11502—(TRG)
Coordinator to Consent
EPIC order: IRB 21734
Order blood type & screen; research sample
TRG will randomize pt (CP vs Placebo)
Approve drug order
Administer study drug
DO NOT TELL PT which treatment they receive!
Post-study blood draw
Send home w/study d/c info sheet

C3PO

If pt COVID Positive

Note: The dotted lines on Page 1 are cut lines to help you get perfect 3.5 x 2” business cards. But if you are using pre-cut business card sheets, use page 2, so that the dotted lines don’t show up on your cards.